Mesoblast (MESO) Depreciation & Amortization (CF) (2016 - 2025)
Mesoblast's (MESO) quarterly Depreciation & Amortization (CF) came in at $2.1 million in Q2 2025, down 14.82% year-on-year from $2.4 million in Q2 2024, and down 14.82% quarter-over-quarter from $2.4 million in Q2 2024.
Mesoblast (MESO) Depreciation & Amortization (CF) (2016 - 2025) Analysis & Trends
Mesoblast has disclosed Depreciation & Amortization (CF) across 10 years of filings, most recently posting $2.1 million for Q2 2025.
- Depreciation & Amortization (CF) for Q2 2025 came in at $2.1 million, down 14.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 million (down 2.35% YoY), and the FY2025 annual result was $2.1 million, down 14.82% from the prior year.
- Depreciation & Amortization (CF) came in at $2.1 million for Q2 2025 at Mesoblast, down from $2.4 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.3 million in Q2 2022 to a low of $990000.0 in Q1 2023.
- The 5-year median for Depreciation & Amortization (CF) is $1.1 million (2022), against an average of $1.7 million.
- Across the five-year window, Depreciation & Amortization (CF) rose 17.81% in 2021 and tumbled 33.82% in 2023, its largest moves.
- Mesoblast's Depreciation & Amortization (CF) stood at $1.1 million in 2021, then fell by 1.54% to $1.1 million in 2022, then soared by 101.84% to $2.2 million in 2023, then increased by 11.55% to $2.4 million in 2024, then retreated by 14.82% to $2.1 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $2.1 million (Q2 2025), $2.4 million (Q2 2024), and $2.2 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Mar 31, 2023 | 990,000.00 |
| Mar 31, 2023 | 990,000.00 |
| Dec 31, 2022 | 1.09 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 3.31 Mn |
| Jun 30, 2022 | 3.31 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Sep 30, 2021 | 1.09 Mn |